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expanding and balloon-mounted stents. A representative balloon-
mounted stent-assisted remodeling of an occluded Optease (Cordis, Inc)
IVCF placed 3 years before is shown in the Fig. Self-expanding stents
were deployed distally from the IVCF site to treat the entire obstructed
segment. Technical success, clinical outcome, and duplex ultrasound
assessment are reported throughout follow-up. Patients were maintained
on chronic anticoagulation therapy.
Results: Five patients (average age, 68; range, 60-77 years) had long-
standing IVCF (average duration, 6.25 years; range, 3-10 years) and debil-
itating venous outflow obstruction with ulceration or venous claudication
despite conservativemanagement. Immediate technical success was achieved
in all patients. There was no perioperative morbidity. All patients noted
marked clinical improvement and duplex documentation of stent patency to
date (average, 4.25 months; range, 1-7 months).
Conclusions: Endovascular recananalization of chronically occluded
IVCFs is technically feasible. Early results suggest the safety and efficacy of
this approach to complex, iatrogenic venous outflow obstruction caused by
chronic IVCF occlusion.
The HeRO Experience: Midterm Report on a Difficult Dialysis
Population
JustinWallace,MD,1 Rabih Chaer,MD,2 EllenD.Dillavou,MD2. 1Uni-
versity of Pittsburgh Medical Center and 2University of Pittsburgh, Pitts-
burgh, Pa
Objective(s): The Hemodialysis Reliable Outflow (HeRO) catheter
has provided an innovative means to obtain hemodialysis access for patients
with severe central venous occlusive disease. The outcomes of this novel
treatmentmodality in a difficult population have yet to be clearly established.
Methods: A retrospective review of HeRO catheter placement from
June 2010 to present was performed. Patient hemodialysis access history,
clinical complexity, complications, and outcomes were analyzed.
Results: HeRO catheter placement was attempted 21 times in 19
patients (52% female), with an 86% success rate (three unsuccessful at-
tempts). All but one was placed in the upper extremity. Mean follow-up after
placement has been 6.8  5.5 months (range, 0.0-17.5 months). The
primary indication for all HeRO catheter placements was central vein
occlusion(s) and need for arteriovenous access. Patients averaged 2.0 previ-
ous (failed) accesses and multiple catheters. Seven patients had significant
arterial issues in one or both upper extremities. Four HeRO catheters
(23.5%), all in women, required ligation and removal for severe steal
symptoms in the immediate postoperative period (P  .01 vs men). Two
deaths not thought to be related to HeRO occurred in the postoperative
period. Three HeROs were placed above fistulas for rescue. All thrombosed
4 months, although fistulas remained open. Average time to initial failure,
including thrombosis or explantation due to steal or infection, was 4.6 4.5
months (range, 0-14.2 months). Of 12 HeROs that functioned 30 days,
average functional time has been 9 months. Two HeROs were removed for
infection at 3.5 and 7.5 months after placement. Secondary patency was
maintained in four patients for a mean duration of 10.4  4.9 months
(range, 6.4-17.5 months), with an average of 4.0  2.2 thrombectomies
(range, 1-6 months) per catheter.
Conclusions: HeRO catheter placement, when used as a last-resort
measure, has been able to provide upper extremity access in patients who
otherwise would not have this option. There is a high complication rate,
however, including a very high incidence of steal in women. HeRO catheters
should continue to be used as a last resort.
HowOften Is Inflow Stenosis a Contributing Factor in the Etiology of
Arteriovenous Access-Induced Ischemic Steal?
Angela A. Kokkosis, MD, Steven Abramowitz, MD, Jonathan Schwitzer,
BS, Scott Nowakowski, MD, Victoria J. Teodorescu, MD, Harry Schanzer,
MD. Mount Sinai Medical Center, New York, NY
Objective(s): To determine how frequent inflow stenosis is a contrib-
uting factor in the etiology of arteriovenous access-induced steal (AVAIS).
Methods: Between October 2001 and December 2011, 17 patients
(47% men) with severe AVAIS (Rutherford stage 2-3) were evaluated in our
center with complete vascular imaging (aortic arch plus upper extremity
imaging). Patient demographics, access history, time to steal symptoms,
preoperative angiographic imaging, and interventions performed were ana-
lyzed. Hemodynamically significant stenosis was defined as50% reduction
in the diameter of the vessel lumen.
Results: The 17 patients were an average age of 61.9 10.4 years, and
47.1% were African Americans. The average time to presentation of steal
symptoms was 158 246 days. All accesses were placed were in the proximal
arm, and 65.7% were with native vein. Imaging studies consisted of angiog-
raphy in 14 patients and computed tomography angiography in three. Five
of the 17 patients (29.4%) had imaging evidence of significant inflow
stenosis. The location of stenosis was the subclavian artery in three and the
brachial artery in two. The interventions subsequently performed were distal
revascularization and interval ligation in 12, ligation in three, and angio-
plasty and stenting in two.
Conclusions: Hemodynamically significant inflow stenosis contrib-
uting to AVAIS is a very prevalent etiologic factor that should not be
ignored. Preoperative angiography should be an important step in the
evaluation and treatment of this condition. Endovascular treatment by
itself may not be curative for patients with steal, but the correction of the
inflow stenosis is important as an adjunct for any other of the corrective
measures.
Outcomes of Arteriovenous Fistula Creation by Location: Does Gender
Matter?
Steven D. Abramowitz, MD, Jonathan Schwitzer, BS, Victoria Teodor-
escu, MD, Angela Kokkosis, MD, Harry Schanzer, MD, Peter Faries, MD,
Ageliki Vouyouka, MD. Mount Sinai Hospital, New York, NY
Objective(s): Prior work suggests that fistula failure is more likely in
women; however, this work has not stratified outcomes by fistula loca-
tion. This study seeks to compare the outcomes of men and women with
suitable vessel diameters on preoperative ultrasound mapping after cre-
ation of radiocephalic (RCF), brachiocephalic (BCF) and brachiobasilic
arteriovenous fistulas (BBF).
Methods: This retrospective study evaluated 580 patients aged 70
years with regular follow-up after creation of arteriovenous fistula. Within
this group, 188 (73 women and 115 men) underwent RCF creation, 233
(113 women and 120 men) underwent BCF creation, and 159 (77 women
and 82 men) underwent BBF creation. Medical records were analyzed for
preoperative ultrasound results, fistula patency, central venous catheter days,
and fistula-related procedures.
Results: The difference in vein diameter among men and women in
the RCF, BCF, and BBF access cohorts was not statistically significant.
Sex did not influence the site of access creation (P  .72). Primary
functional and cumulative (primary assisted and secondary) patency of RCFs at
1 year forwomen andmenwas 32% vs 51% (P .02) and 64% vs 77% (P .03),
respectively. Women vs men had a greater number of catheter days (88 vs 58,
P  .01) and more fistula-related procedures (1.4 vs 0.8, P  .01). Primary
functional and cumulative patency for BCFs at 1 year for women and men was
44% vs 58% (P .04) and 72% vs 85% (P .03), respectively. Women vs men
had a greater number of catheter days (74 vs 61, P  .05) and more fistula-
related procedures (1.6 vs 0.7, P  .04). Primary functional and cumulative
patency at 1 year for BBFs in women and men was 61% vs 68% (P  .51) and
78% vs 87% (P .21), respectively. Women had no difference in the number of
catheter days (P .38) or fistula-related procedures (P .52).
Conclusions: These data suggest it is possible to achieve functional
arteriovenous fistula in women regardless of fistula location. However,
there exist statistically significant differences in fistula-related outcomes
between men and women undergoing creation of RCFs or BCFs. There
appears to be no difference in sex-related outcomes for BBFs.
Readmission Rates of Tunneled Dialysis Catheters Compared to Per-
manent Arteriovenous Access
SamTyagi, Arthur Yushuva, Shinichi Fukuhara, David Lucido, Erez Dayan,
Stephen Haveson. Beth Israel Medical Center, New York, NY
Objective(s): The current methodology in treating patients with
end-stage renal disease (ESRD) includes dialysis via arteriovenous fistulas
(AVF), arteriovenous grafts (AVG), and tunneled dialysis catheters
(TDCs). The standard treatment is to obtain permanent hemodialysis
access (AVF and AVG) during that admission. TDCs can be placed
quickly for emergency dialysis, but hospital stays are sometimes length-
ened to place permanent access as an inpatient. Current practice may
increase hospital length of stay, cost, and associated nosocomial comor-
bidities. We propose that permanent access placement in every patient
presenting with ESRD on initial admission is not necessary. The TDC
should be placed and the permanent access created as an elective,
outpatient operation. We were interested in comparing outpatients dia-
lyzed via permanent access with patients dialyzed with TDCs to assess
whether it is safe and cost-effective to discharge a patient with a TDC.
Our objective was to observe the readmission rates, reasons for readmis-
sion, and problems in the two groups associated with access.
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Table I. Access vs number readmissions per access group
Access
Patients
(No.)
Days
1-15 16-30 31-90 Total
AVF  AVG 175 10 (3)a 24 (3) 54 (5) 88 (11)
TDC 125 11 (2) 12 (1) 49 (6) 62 (9)
aParenthesis for admissions directly related to access (ex: failure, thrombosis,
infection).
Methods: This was a retrospective analysis of 300 patients between
March 2009 and July 2010 already undergoing hemodialysis via TDC, AVF,
or AVG for readmissions at 15, 30 and 90 days.
Results: There was no statistically significant difference in the 15-, 30-,
and 90-day readmission rate in the patients with TDCs compared with
permanent access (Table I and Table II).
Conclusions: TDCs were shown to be as safe and cost-effective as
permanent access during these time periods. Shortening hospital stay by
discharging patients with TDCs and electively placing permanent access
could result in better outcomes and significant cost savings.
Table II. Negative binomial regression analysis of readmissions of TDCs
vs permanent access
Time period RR (95% CI) P
1 to 15 days 1.38 (0.56-3.37) .482
16 to 30 days 0.67 (0.33-1.35) .261
31 to 90 days 1.24 (0.81-1.91) .316
Overall 1.09 (0.75-1.58) .637
CI, Confidence interval; RR, risk ratio.
Early and Late Clinical Outcome of Percutaneous Transluminal Stent-
ing of the Celiac and Superior Mesenteric Arteries: Our Experience
Over the Past Decade
Ali F. AbuRahma,MD,1 John E. Campbell, MD,1 Patrick A. Stone, MD,1
Stephen M. Hass, MD,1 Albeir Y. Mousa, MD,1 Aravinda Nanjundappa,
MD,1 L. Scott Dean, PhD, MBA,2 Tammi Keiffer, RN2. 1Robert C. Byrd
Health Sciences Center of West Virginia University, and 2Charleston Area
Medical Center, Charleston, WV
Objective(s): Several authorities have proposed stenting of the
superior mesenteric artery (SMA)/celiac arteries (CA) as the primary
treatment for patients with chronic mesenteric ischemia. However, most
of these reports had a small sample size and short follow-up period. This
is one of the largest studies to date to analyze early and late outcomes of
stenting of SMA/CA stenosis.
Methods: During a 10-year period, 83 patients were treated and
underwent clinical follow-up and duplex ultrasound examinations to
evaluate long-term patency. A Kaplan-Meier life-table analysis was used
to estimate freedom from in-stent stenosis and late symptoms and
survival rates.
Results: Outcomes for 54 SMAs and 51 CA were analyzed. The initial
technical and clinical success rates were 97% and 96%, respectively, with 2% periop-
erative morbidity and 2% mortality. The primary late clinical success rate was 59%
and the late70% in-stent stenosis ratewas 54% at amean follow-up of 31months
(range, 1-124months).Rates for freedomfrom late recurrent symptomswere83%,
77%,70%,70%, and65%at1,2,3,4, and5years, respectively.Primarypatency rates
of the whole series were 68%, 48%, 36%, 26%, and 18% at 1, 2, 3, 4, and 5 years,
respectively, and the assisted primary patency rates were 79%, 60%, 51%, 41%, and
32%. The primary patency rates for SMA at 1, 2, 3, 4, and 5 years were 68%, 45%,
31%,24%, and16%, respectively, and theassistedprimary rateswere79%,62%,50%,
39%, and 28%. The primary patency rates for CA were 68%, 50%, 40%, 29%, and
21%, and the assisted primary rates were 79%, 58%, 52%, 42%, and 36% for 1, 2, 3,
4, and 5 years, respectively. There were no significant differences in primary or
assisted primary patency between SMA (P  .5605) or CA (P  0.5782; Fig).
Secondary intervention was done in 30% of the series.
Conclusions: Stenting of SMA/CA stenosis has a high technical and
early clinical success rates, with a satisfactory late clinical outcome;
however, it is associated with high rates of late in-stent stenosis and
intervention.
Table.
Time,
months At risk
SMA
Cum APP SE At risk
Celiac
Cum APP SE
0 51 0.9608 0.0272 54 0.9815 0.0183
1 38 0.9608 0.0272 46 0.9601 0.0277
6 33 0.9074 0.0448 39 0.8926 0.0456
12 26 0.7864 0.0684 32 0.7926 0.0621
24 19 0.6209 0.0852 19 0.5845 0.082
36 11 0.4975 0.0943 13 0.5158 0.0856
48 8 0.3918 0.0998 9 0.4232 0.0925
60 3 0.2799 0.0978 6 0.3627 0.0971
Endovascular Aneurysm Repair in the Elderly: Trends and Outcomes
From the National Inpatient Sample
Nchang Azefor, MD,1 Brian D. Park, MD,1 Chun-Chih Huang, PhD,1
Cameron Akbari, MD,1 Frederick Beavers, MD,1 David Deaton, MD,2
Robyn Macsata, MD,3 Sean O’Donnell, MD,1 Susanna Shin, MD,1 John
Ricotta, MD1. 1The Washington Hospital Center, the 2Georgetown Uni-
versityHospital, and the 3Washington VAMedical Center,Washington, DC
Objective(s): This study used the a nationwide data set to identify
trends in endovascular abdomianal aortic aneurysm (AAA) repair (EVAR)
utilization and outcomes during a 5-year period.
Methods: The Nationwide Inpatient Sample database was queried
for the years 2005 to 2009. Number of EVAR cases, ratio of EVAR/open
repair (OR), major clinical outcomes, hospital costs and discharge status
were analyzed by decade. Interval data were compared with analysis of
variance and proportions via 2 tests.
Results: There were 174,714 AAA repairs (124,869 EVAR) identi-
fied. The ratio of EVAR/OR increased with increasing age. Between
2005 and 2009, the number of AAA repairs in the elderly increased by
21% (7179 vs 8554), and EVAR in patients aged 80 years increased by
50% (5057 vs 7650 P  .05). In 2009, 85% of AAA repairs in patients
aged 80 years were EVAR, and 25% of EVAR were performed in
patients aged 80 years, equivalent to age 60-69 years. The in-hospital
mortality rate remained acceptable in all age groups. EVAR-associated
mortality, length of stay, hospital costs, and discharge to skilled nursing
facility increased with each successive decade of life (P  .05). Postop-
erative myocardial infarction and acute renal failure also increased with
increasing age (P  .05). EVAR results by decade are presented in the
Table.
Conclusion: One-quarter of EVAR are performed in patients aged
80 years based on low mortality rates. There is an age-dependent
increase in death, complications, hospital costs, and discharge to ex-
tended care facilities. Such factors and long-term risk of aneurysm-related
death should be considered when evaluating the appropriateness of
elective aneurysm repair in the elderly.Fig.
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